TY - JOUR T1 - Relation of spice consumption with COVID-19 first wave statistics (infection, recovery and mortality) across India JF - medRxiv DO - 10.1101/2022.06.08.22275684 SP - 2022.06.08.22275684 AU - Vedvati Bhapkar AU - Supriya Bhalerao Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/06/22/2022.06.08.22275684.abstract N2 - Background & Objectives The recovery and mortality statistics for COVID-19 first wave considerably differed in different states & Union territories (UT) of India. Though dependent on several factors, relation of diet and immunity is well-established. Spices are an essential part of Indian cuisine. Apart from adding flavors and colors to the food, their importance has been traditionally known in disease prevention and cure. Thus, present study was carried out to assess relation of spice consumption with COVID-19 first wave statistics in India.Methods The spice consumption data were retrieved from ‘Household Consumption of Various Goods and Services in India’ from 68th round (2011-12) of survey conducted by National Sample Survey Organization (NSSO). Spices for which, consumption data was available, viz., ginger (Zingiber officinale), garlic (Allium sativum), cumin (Cuminum cyminum), coriander (Coriandrum sativum), turmeric (Curcuma longa), black pepper (Piper nigrum), chili (Capsicum annuuam), tamarind (Tamarandus indica) and ‘other spices’ were selected for analysis. The COVID-19 first wave data for individual states and UTs were retrieved as total number of cases, number of cured/discharged/migrated cases and total number of deaths due to COVID-19, in a cumulative form. It was normalized ‘per million’ population of respective states and UT. The correlation of individual spice consumption and COVID-19 statistics was analyzed.Results and Conclusions Spices were consumed across all India with a varied range. The highest consumed spice was ginger. Its highest consumption was in Mizoram (185 gm/30 days) and least in Jammu & Kashmir (23gm/30 days). The highest consumption of ‘Other spices’ were observed in Lakshadweep (149 gm/30 days), which incidentally reported zero COVID-19 cases. Tamarind consumption showed positive correlation (r = 0.4724) with total number of cases per million population, recovered/migrated/cured cases (r = 0.4948). The consumption of cumin exhibited a weak positive correlation (r = 0.5011) with total deaths per million population. However, most of these correlations were statistically insignificant. The findings from this study provide a basic framework and understanding for future studies. These findings can help to predict preventive/ mitigating or curative usage of these spices. Should similar scenario occur in future, these findings can provide some vital base to act as adjuvant management. As the unspecified and under-explored ‘Other spices’ category showed promising correlation, more attention needs to be given to them too, along with mostly studied spices like ginger and turmeric.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The spice consumption data were retrieved from Household Consumption of Various Goods and Services in India from 68th round (2011-12) of consumption expenditure survey conducted by National Sample Survey Organization (NSSO). The COVID-19 data for individual states and UT of India were retrieved from the website of Ministry of Health & Family Welfare, Govt. of India.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://catalog.ihsn.org/catalog/3281/study-description and https://www.mohfw.gov.in/ ER -